Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Am Heart J ; 235: 97-103, 2021 05.
Article in English | MEDLINE | ID: mdl-33567319

ABSTRACT

BACKGROUND: Interventional cardiologists receive feedback on their clinical care from a variety of sources including registry-based quality measures, case conferences, and informal peer interactions. However, the impact of this feedback on clinical care is unclear. METHODS: We interviewed interventional cardiologists regarding the use of feedback to improve their care of percutaneous coronary intervention (PCI) patients. Interviews were assessed with template analysis using deductive and inductive techniques. RESULTS: Among 20 interventional cardiologists from private, academic, and Department of Veterans Affairs practice, 85% were male, 75% performed at least 100 PCIs annually, and 55% were in practice for 5 years or more. All reported receiving feedback on their practice, including formal quality measures and peer learning activities. Many respondents were critical of quality measure reporting, citing lack of trust in outcomes measures and poor applicability to clinical care. Some respondents reported the use of process measures such as contrast volume and fluoroscopy time for benchmarking their performance. Case conferences and informal peer feedback were perceived as timelier and more impactful on clinical care. Respondents identified facilitators of successful feedback interventions including transparent processes, respectful and reciprocal peer relationships, and integration of feedback into collective goals. Hierarchy and competitive environments inhibited useful feedback. CONCLUSIONS: Despite substantial resources dedicated to performance measurement and feedback for PCI, interventional cardiologists perceive existing quality measures to be of only modest value for improving clinical care. Catherization laboratories should seek to integrate quality measures into a holistic quality program that emphasizes peer learning, collective goals and mutual respect.


Subject(s)
Cardiologists/standards , Coronary Artery Disease/surgery , Perception/physiology , Percutaneous Coronary Intervention , Practice Patterns, Physicians' , Registries , Female , Humans , Male , Retrospective Studies
2.
J Med Food ; 14(4): 353-9, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21370965

ABSTRACT

Diabetes is accompanied by lipid abnormalities, which contribute significantly to cardiovascular morbidity and mortality in diabetic patients. We previously demonstrated the potent antihyperglycemic activity of the active principle (fraction II from Sephadex LH 20 chromatography [LH II]) isolated from ethanolic seed extract of Eugenia jambolana in diabetic rabbits. In the present study, the efficacy of LH II was evaluated for its hypolipidemic activity in alloxan-induced mildly diabetic (MD) and severely diabetic (SD) rabbits. Phytochemical investigation of LH II by various structural spectra showed the presence of saturated fatty acid, Δ(5) lipid, and sterol. Oral administration of LH II (10 mg/kg of body weight) for 21 days resulted in improved glycemic control in both MD and SD rabbits. After treatment with LH II, serum total cholesterol, triglycerides, high-density lipoprotein cholesterol, and the total cholesterol/high-density lipoprotein cholesterol ratio were significantly improved. LH II also resulted in significant (P < .001) improvement in 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and levels of total lipids and glycogen in both MD and SD rabbits. Thus, the present study demonstrates that LH II possesses potent hypolipidemic activity and efficacy in both MD and SD rabbits.


Subject(s)
Diabetes Mellitus, Experimental/drug therapy , Hypolipidemic Agents/pharmacology , Phytotherapy , Plant Extracts/therapeutic use , Seeds/chemistry , Syzygium/chemistry , Administration, Oral , Alloxan , Animals , Blood Glucose/analysis , Cholesterol, HDL/blood , Cholesterol, LDL/blood , Insulin/blood , Male , Rabbits , Triglycerides/blood
3.
J Med Food ; 13(3): 528-34, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20521978

ABSTRACT

Cassia auriculata traditionally has been used to treat diabetes from ancient times. The objective of the present study was to investigate the mechanism of action for the antidiabetic activity of aqueous leaf extract of C. auriculata (CLEt) in streptozotocin-induced mildly diabetic (MD) and severely diabetic (SD) rats. CLEt was orally administered to MD and SD rats at a dose of 400 mg/kg once a day for 15 days. CLEt-treated MD and SD rats showed significant reduction in fasting blood glucose. Assessment of plasma insulin and C-peptide following treatment with CLEt revealed significant elevation in their levels. Administration of CLEt enhanced the activity of hepatic hexokinase and phosphofructokinase and suppressed glucose-6-phosphatase and fructose-1,6-bisphosphatase in both MD and SD rats. A significant rise in glycogen content was also observed in both liver and muscles of CLEt-fed MD and SD rats. Histopathological examination of pancreatic sections revealed increased number of islets and beta-cells in CLEt-treated MD as well as SD rats. The findings of the study suggest that the antidiabetic effect of CLEt could be due to its insulinogenic action. In addition, impaired glucose homeostasis was improved by feeding the extract through amelioration in the carbohydrate metabolic pathways. Thus, the extract may exert an antidiabetic effect through pancreatic as well as extrapancreatic action.


Subject(s)
Cassia/chemistry , Diabetes Mellitus/drug therapy , Hypoglycemic Agents/administration & dosage , Plant Extracts/administration & dosage , Streptozocin/adverse effects , Animals , Blood Glucose/drug effects , C-Peptide/blood , Diabetes Mellitus/chemically induced , Diabetes Mellitus/metabolism , Disease Models, Animal , Glucose/metabolism , Glycogen/metabolism , Humans , Insulin/blood , Liver/metabolism , Male , Muscle, Skeletal/metabolism , Plant Leaves/chemistry , Random Allocation , Rats , Rats, Sprague-Dawley , Rats, Wistar , Streptozocin/administration & dosage
4.
Indian J Exp Biol ; 47(12): 974-80, 2009 Dec.
Article in English | MEDLINE | ID: mdl-20329701

ABSTRACT

Oral administration of aqueous leaf extract of Cassia auriculata L. (100, 200, 400 and 600 mg/kg body wt daily for 21 days) to alloxan-induced mild diabetic (MD) and severe diabetic (SD) rabbits produced dose dependent fall in fasting blood glucose up to 400 mg/kg dose from day 3 to day 21. Further, a significant elevation in the levels of insulin and reduction in glycosylated haemoglobin (HbA1c) was observed in both MD and SD rabbits when treated with 400 mg/kg dose of the extract. The significant decrease in serum levels of triglycerides (TG), total cholesterol (TC) and low-density lipoprotein-cholesterol (LDL-C) with a concomitant increase in high-density lipoprotein-cholesterol (HDL-C) was exhibited by MD as well as SD rabbits following treatment with the extract. Atherogenic indices (TG/HDL-C, TC/HDL-C and LDL-C/HDL-C) were also significantly reduced in both diabetic models of rabbits fed with the extract. Effect of the extract at 400 mg/kg dose was comparable to that of glibenclamide (600 microg/kg), a reference antidiabetic drug. Thus, the present study demonstrated that aqueous leaf extract of C. auriculata can be a possible candidate for antidiabetic drug.


Subject(s)
Atherosclerosis/drug therapy , Blood Glucose/drug effects , Cassia/chemistry , Diabetes Mellitus, Experimental/drug therapy , Plant Extracts/pharmacology , Alloxan , Animals , Atherosclerosis/metabolism , Blood Glucose/metabolism , Cholesterol, HDL/blood , Cholesterol, LDL/blood , Diabetes Mellitus, Experimental/metabolism , Glyburide/pharmacology , Glycated Hemoglobin/metabolism , Hypoglycemic Agents/pharmacology , Insulin/blood , Plant Leaves/chemistry , Rabbits , Triglycerides/blood
5.
Clin Biochem ; 41(7-8): 453-8, 2008 May.
Article in English | MEDLINE | ID: mdl-18280807

ABSTRACT

OBJECTIVES: The purpose of this study was to explore the association between lipoprotein (a) [Lp(a)] levels, apo(a) isoforms and family history of premature coronary artery disease (CAD) in young Asian Indians. DESIGN AND METHODS: 220 patients (age <40 years) with angiographic evidence of CAD and 160 age matched healthy controls were enrolled for the study. Thirty one percent of the patients and 17% of the controls had positive family history (PFH) of premature CAD. Plasma Lp(a) levels were determined by ELISA and apo(a) isoform size was determined using high-resolution immunoblotting method. RESULTS: Median plasma Lp(a) levels were 2.5 times higher in patients as compared to controls (30 mg/dL vs 12.7 mg/dL; p<0.05). The patient group having a heterozygous apo(a) isoform pattern showed higher Lp(a) levels as compared to the homozygous group (44.0+/-38.7 vs 28.0+/-26.4 mg/dL; p<0.001). Further low molecular weight apo(a) isoforms (LMW; <22 KIV repeats) were prevalent among CAD patients with PFH as compared to negative family history (62% vs 14%, p<0.05) and this group had the highest Lp(a) levels. Stepwise regression analysis showed that Lp(a) levels and not the apo(a) isoform size, entered the model as significant independent predictors of CAD in young Asian Indians. CONCLUSIONS: This study suggests that elevated Lp(a) levels confer genetic predisposition to CAD in young Asian Indians. Thus determination of Lp(a) levels along with other risk factors should be used to assess overall risk for CAD in this ethnic group.


Subject(s)
Apolipoproteins A/blood , Asian People/genetics , Coronary Artery Disease/blood , Genetic Predisposition to Disease/genetics , Lipoprotein(a)/blood , Adult , Apolipoproteins A/genetics , Coronary Artery Disease/epidemiology , Coronary Artery Disease/genetics , Female , Humans , India/epidemiology , Lipoprotein(a)/genetics , Male , Middle Aged , Predictive Value of Tests , Protein Isoforms/blood , Protein Isoforms/genetics
6.
Clin Chim Acta ; 359(1-2): 101-8, 2005 Sep.
Article in English | MEDLINE | ID: mdl-15893742

ABSTRACT

BACKGROUND: Oxidative stress has been implicated in vascular complications of diabetes mellitus (DM). This study aims to evaluate the relationship between postprandial hypertriglyceridemia (PP-HTG) and oxidative stress in Indian patients of type 2 DM with macrovascular complications. METHODS: Plasma triglycerides (TG), thiobarbituric acid reactive substances (TBARS), erythrocyte reduced glutathione (GSH) and superoxide dismutase (SOD) were measured in fasting and postprandial (PP) state at 2, 4, 6 and 8 h after a high fat meal challenge in controls (Group I) and patients of type 2 DM without (Group II) and with macrovascular complications (Group III). RESULTS: Postprandial TGs increased significantly in patients with type 2 DM, which showed an exaggerated response to high fat meal challenge in Group III as compared to Group II. Highest PP-TBARS were also observed in Group III which correlated positively with TG. However, GSH and SOD were lower in both groups of diabetics as compared to controls. CONCLUSIONS: The magnitude of PP-HTG appears to be the major determinant of oxidative stress in type 2 DM, which along with a compromised antioxidant status may lead to endothelial dysfunction and macrovascular complications.


Subject(s)
Diabetes Mellitus, Type 2/metabolism , Diabetic Angiopathies/metabolism , Hypertriglyceridemia/blood , Oxidative Stress , Postprandial Period , Adult , Case-Control Studies , Diabetes Mellitus, Type 2/complications , Diabetic Angiopathies/complications , Female , Glutathione/blood , Humans , Male , Middle Aged , Superoxide Dismutase/blood , Thiobarbituric Acid Reactive Substances/metabolism , Triglycerides/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...